E213 - Metabolic dysfunction–associated fatty liver disease an update

episode

Australian Prescriber Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Your partner wants profit. You want freedom. Now what? 22 min · 16 Sep 2026 · The Optometry Success Podcast

Board of County Supervisors Meeting - Work Session - Sep 15, 2026 3h 17m · 15 Sep 2026 · Prince William County Board of Supervisors

Finance and Budget Committee - Sep 15, 2026 1h 43m · 15 Sep 2026 · Prince William County Finance and Budget Committee

Sept. 15, 2026 Board of Supervisors Meeting 8h 46m · 15 Sep 2026 · Fairfax County Board of Supervisors

The Art of True Happiness | Dr. Arthur Brooks 2h 49m · 14 Sep 2026 · Huberman Lab

The Chris Wolfe Podcast: The Power of Quality Supplements 48 min · 14 Sep 2026 · EyeCode Media

Report any issue

Source

Recorded27 Apr 2026

Publisheraustralianprescriber.libsyn.com ↗

Handlerec:18139559

Show notes

Laura Beaton talks to hepatology research fellow Richard O'Halloran about his paper on metabolic dysfunction–associated fatty liver disease (MAFLD). Richard outlines risk factors and comorbidities to consider, and diagnostic tests for MAFLD. The conversation also covers management of MAFLD through risk stratification, addressing health risk behaviours, and surveillance. Read the full article in Australian Prescriber.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in